Open AccessTreatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
Author(s) -
Mohammed A. Babatin,
Abdullah S Alghamdi,
Abdullah M. Assiri,
Haziz Albiladi,
Hammad S. Alothmani,
Mohammed H Mogharbel,
Wedad Mahallawi,
Tarik Asselah,
Faisal M. Sanai
Publication year - 2019
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/sjg.sjg_189_18
Subject(s) - medicine , sofosbuvir , ledipasvir , adverse effect , regimen , hepatitis c , gastroenterology , hepatitis c virus , clinical endpoint , prospective cohort study , ribavirin , surgery , randomized controlled trial , immunology , virus
Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline characteristics. Data on treating HCV GT4 with LDV/SOF are limited. In this prospective cohort study, the efficacy and safety of 8 weeks treatment duration with LDV/SOF was evaluated in HCV GT4 patients in Saudi Arabia.